The FDA approved Actavis Pharma, Inc.'s application for the generic oral version of Fioricet With Codeine (butalbital, acetaminophen, caffeine, and codeine phosphate) on June 10, 2004, which is expected to intensify price pressure and erode market share for the brand-name product within the migraine analgesic market.